Investor Alert

London Markets Open in:


Science and Technology


AI-assisted robots could reduce surgery complications by 5 times

  • AI-assisted robots could reduce surgery complications by 5 times AI-assisted robots could reduce surgery complications by 5 times 3:35
    China's Tiangong vs. International Space Station: Tech, Design Unpacked China's Tiangong vs. International Space Station: Tech, Design Unpacked 6:55
    Why TikTok Has Become a Launchpad for Entrepreneurs Why TikTok Has Become a Launchpad for Entrepreneurs 6:39
    WSJ Opinion: A Virginia PTA Purge of Asians WSJ Opinion: A Virginia PTA Purge of Asians 3:30
5:28 a.m. Sept. 22, 2021 - By Lucas Berenbrok
Hearing aids could soon cost less than $1,000 and be bought at the drugstoreRules on how over-the-counter hearing aids can be marketed and sold are now being written.
3:34 a.m. Sept. 22, 2021 - By Jaimy Lee
CDC committee to meet today and Thursday to again discuss BioNTech and Pfizer's COVID-19 boosterA Centers for Disease Control and Prevention committee is Wednesday and Thursday to again discuss the science and possible administration plan for BioNTech SE and Pfizer Inc.'s COVID-19 booster shot. The CDC's Advisory Committee on Immunization Practices sets out the guidelines for how vaccines should be used in the U.S. The Food and Drug Administration has not approved or authorized an extra dose of the BioNTech and Pfizer vaccine except in people who are immuno-compromised, and an influential FDA committee last week recommended that boosters to older people and those who are at higher risk of severe disease. Some experts have suggested that the FDA decision is coming this week.
3:00 a.m. Sept. 22, 2021 - By MarketWatch
AI-assisted robots could reduce surgery complications by 5 timesAbout 100,000 people die annually due to medical errors, according to the National Center for Biotechnology Information. Here's how AI-assisted robots could improve surgical outcomes.
6:59 p.m. Sept. 21, 2021 - By Wallace Witkowski
Freshworks IPO: 5 things to know about the customer software-as-a-service providerFreshworks Inc. is scheduled to start trading on Wednesday in what's expected to be the biggest public debut in a week jam packed with initial public offerings.
5:45 a.m. Sept. 20, 2021 - By Filippo Menczer
Censorship will never be able to stop the spread of viral misinformation on social media - here's an idea that might workHumans have always been easily misled, but what's new is how fast the lies can spread.
3:47 a.m. Sept. 20, 2021 - By Jaimy Lee
FDA panel recommends Pfizer’s COVID-19 booster for 65 and older, but not for the general publicA group of advisors to the Food and Drug Administration on Friday reframed a proposed approval of BioNTech and Pfizer's COVID-19 booster for the general population, and it instead recommended authorization of an additional dose of the vaccine to people at least 65 years old and those at high risk for severe disease.
5:10 a.m. Sept. 17, 2021 - By Jaimy Lee
Scientists continue to say there isn't enough evidence to make COVID-19 boosters available to all AmericansAn influential Food and Drug Administration committee is set to meet Friday to discuss whether the regulator should approve BioNTech and Pfizer's COVID-19 booster shot
6:15 a.m. Sept. 16, 2021 - By Barbara Kollmeyer
Emotional AI and other 'moonshot' technologies could grow to $6 trillion market by 2030, says Bank of AmericaOur call of the day has 14 ideas on future technologies that could be the next big thing for investors, if they don't choose to ignore it.
5:32 p.m. Sept. 15, 2021 - MarketWatch.com
SpaceX blasts off Inspiration4, making history with first all-civilian crewSpaceX’s first private flight blasted off Wednesday night with two contest winners, a health care worker and their rich sponsor, the most ambitious leap yet in space tourism.
4:23 p.m. Sept. 15, 2021 - MarketWatch.com
U.S., U.K. to help Australia acquire nuclear subs under new security alliancePresident Joe Biden announced Wednesday that the United States is forming a new Indo-Pacific security alliance with Britain and Australia that will allow for greater sharing of defense capabilities, a move that could deepen a growing chasm in U.S.-China relations.
1:20 p.m. Sept. 15, 2021 - By Jaimy Lee
FDA says COVID-19 vaccines continue to protect people in the U.S. from severe diseaseThe Food and Drug Administration said Wednesday that observational studies have had mixed findings assessing whether the efficacy for BioNTech SE and Pfizer Inc.'s COVID-19 vaccine is declining as a result of time or the delta variant but in general the vaccines available in the U.S. continue to protect people against severe disease and death. The FDA's was published Wednesday in advance of an advisory committee meeting set for Friday; at that meeting, a group of independent experts will discuss and then vote on whether they think the FDA should approve a COVID-19 booster dose for people who are at least 16 years old or older. The FDA is not required to follow the advice of the committee but often does. Pfizer's document for the meeting was also published on Wednesday; it cited the need to look at the when it comes to making a regulatory decision about a third dose of its vaccine. The FDA's document, on the other hand, said it has not independently verified all potentially relevant studies.
12:38 p.m. Sept. 15, 2021 - By Nicole Lyn Pesce
How to watch the SpaceX Inspiration4 mission launchThe all-American, all-civilian crew will orbit the Earth for three days
10:43 a.m. Sept. 15, 2021 - By Greg Robb
House Democrats want curbs on big-bank lending to fossil-fuel industryProgressive House Democrats on Wednesday introduced a measure that would require the Federal Reserve to make sure that the largest banks start to reduce their lending to the fossil-fuel industry.
10:30 a.m. Sept. 15, 2021 - By Victor Reklaitis
Biden to announce deal with U.K., Australia on sharing defense technology: reportsPresident Joe Biden on Wednesday will announce a new effort with the U.K. and Australia to share advanced defense technologies in a bid to counter China, according to reports from and . The White House said Biden is due to speak at 5 p.m. Eastern on a "national security initiative," and he will be joined virtually by U.K. Prime Minister Boris Johnson and Australian Prime Minister Scott Morrison.
8:50 a.m. Sept. 15, 2021 - By Tomi Kilgore
Indaptus Therapeutics stock nearly triples on heavy volume after allowance for patent of platform technology Shares of Indaptus Therapeutics Inc. nearly tripled on massive volume in midday trading, to bounce off the previous session's record closing low, after the developer of treatments for hepatitis and HIV announced the allowance of a patent for its platform technology. The stock was up as much as 307.8% at a six-month high of $28.83 before paring gains to be up 184.3%. Trading volume exploded to 119.2 million shares, compared with the full-day average of just 227,600 shares. The stock was the biggest gainer and third-most active on major U.S. exchanges. The company said before the open that its patent titled "Methods of Treatment of Infections Using Bacteria," provides broad protection for the application of the company's platform technology alone and in combination with standards of care for the treatment and inhibition of hepatitus B virus and human immunodeficiency virus (HIV) infections. "This notice of allowance gives us the optionality to confidently pursue our technology in viral diseases and/or to partner it for further development," said Chief Executive Jeffrey Meckler. The stock has now gained 45.7% year to date, while the iShares Biotechnology ETF has tacked on 13.2% and the S&P 500 has advanced 19.0%.
5:29 a.m. Sept. 15, 2021 - By Jaimy Lee
Pfizer cites 'totality' of clinical data in bid for COVID-19 booster approvalShares of Pfizer Inc. gained 0.1% in premarket trading on Wednesday after the drug maker said the "totality" of clinical data indicates that people who are at least 16 years old and were vaccinated with the COVID-19 shot that it developed with BioNTech SE should get a booster after six months. In a published Wednesday morning by the Food and Drug Administration in advance of an advisory committee meeting set for Friday, Pfizer said its Phase 3 substudy examined 306 people between the ages of 18 and 55 years old who got a third dose. It found that an extra dose is considered safe and increased neutralizing antibody titers against the original strain of the virus as well as the beta and delta variants to a higher rate than what was reported after two doses in the clinical trials last year. Younger participants were more likely to report systemic events after the second and third doses than the first dose; fever was more common after the third dose. No adverse events were reported in the first month after the third dose. Pfizer also cited research conducted by Israel, the Centers for Disease Control and Prevention, and the hospital system Kaiser Permanente in the document, saying that data from Israel "suggest reduced effectiveness against severe disease could eventually follow observed reductions in effectiveness against SARS-CoV-2 infections." Pfizer's stock is up 21.4% this year, while the S&P 500 has gained 18.9%.
4:57 a.m. Sept. 15, 2021 - Barrons.com
Enough Hand-Wringing Over the Science. Bring on the Boosters. I gave some of the earliest Covid-19 vaccines outside a rural South Carolina hospital, writes Dr. Allen Wenner. They're safe, and we need boosters.
2:34 a.m. Sept. 15, 2021 - By Tomi Kilgore
Procept BioRobotics upsized IPO prices above the expected range, valuing company at $1 billionProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol "PRCT." With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.
12:13 p.m. Sept. 14, 2021 - Barrons.com
Chevron Is Going Low-Carbon. Investors Are Skeptical. The oil giant is betting big on renewable natural gas and other renewable fuels often made from plants or animal waste.
11:05 a.m. Sept. 14, 2021 - By Tomi Kilgore
Globalstar's stock takes a dive after Apple didn't say its new iPhone supports satellite communicationsShares of Globalstar Inc. took an afternoon dive Tuesday, as investors expressed disappointment that Apple Inc. did not say its new iPhone 13s would support satellite communications. The mobile satellite services company's stock sank 19.4%, after being down 5.3% just before the start of . The , after the that Apple would work with Globalstar as it added satellite communications to its next iPhone. The stock had climbed another 14.5% from Aug. 30 to the five-year closing high of $2.69 on Sept. 8, before pulling back. The stock has still rocketed 442.9% year to date, while the S&P 500 has advanced 18.3%.
8:00 a.m. Sept. 14, 2021 - By MarketWatch
Fund managers haven’t been this pessimistic on the economy since the early days of the pandemicFund managers are keeping their cyclical stock bets while souring on the economy.
5:00 a.m. Sept. 14, 2021 - By MarketWatch
Surge in U.S. consumer prices slows in August, CPI shows. Has inflation peaked?The cost of living rose in August at the slowest pace in seven months and signaled a big surge in inflation this year may have peaked, but Americans probably aren't going to get much relief from higher prices anytime soon.
4:38 a.m. Sept. 14, 2021 - By Jaimy Lee
Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year endMerck & Co. Inc. said it expects the company's experimental oral antiviral treatment for COVID-19 could get emergency authorization by the end of the year. "We expect to be able to see clinical data here in the back half of the year and still have the potential for an interim analysis and potential for emergency use authorization before year end," Merck CEO Robert Davis told investors at the Morgan Stanley Global Healthcare Conference on Monday. Merck and Ridgeback Biotherapeutics Inc. have been testing the investigational therapy, molnupiravir, in a Phase 3 clinical trial. There are few authorized or approved new COVID-19 treatments beyond the monoclonal antibodies developed by Eli Lilly & Co. , GlaxoSmithKline and Vir Biotechnology Inc. , and Regeneron Pharmaceuticals Inc. and Gilead Sciences Inc.'s Veklury. The medical community has called for easy-to-take medications that can treat the disease caused by SARS-CoV-2. The U.S. has already purchased 1.7 million courses of molnupiravir, dependent on authorization from regulators. Merck's stock is down 7.0% for the year, while the broader S&P 500 is up 18.9%.
1:00 p.m. Sept. 13, 2021 - By MarketWatch
Here are two large tech stocks to avoid, according to Goldman SachsThere's still some opportunity among large-cap internet stocks, but investors should steer clear of two names, according to Goldman Sachs.
8:30 a.m. Sept. 11, 2021 - By Abby Schultz
What It’s Like to Make an NFTPenta invited artists George Clinton and Tom Friedman to create works to be minted and sold on SuperRare’s platform
6:41 a.m. Sept. 11, 2021 - By W. Brad Johnson David G. Smith
Men must hold other men accountable when they see women being harassed. Here's what you can doThree strong responses to inappropriate behavior.
11:00 a.m. Sept. 10, 2021 - MarketWatch.com
Since the start of the pandemic, 130 Black morticians have died in the U.S. from COVID-19When the last mourners departed and funeral director Shawn Troy was left among the headstones, he wept alone.
10:36 a.m. Sept. 10, 2021 - By Tomi Kilgore
Daily COVID-19 deaths rise to 6-month high, and Biden's 'patience is wearing thin' for the unvaccinatedPresident Biden is getting tough, not only on the coronavirus that causes COVID-19, but also on those refusing to get vaccinated, as the daily death toll is still rising to the highest levels seen in six months.
8:05 a.m. Sept. 10, 2021 - Barrons.com
The U.S. and China Need Couples Therapy, Not a Divorce Lawyer Presidents Biden and Xi spoke on phone the for the first time in months. It's never too late to start fresh.
5:12 a.m. Sept. 10, 2021 - By Victor Reklaitis
Infrastructure bill mandates new technology to prevent drunk driving — here's how it would workWith more than 2,700 pages of text, the bipartisan infrastructure bill is chock-full of provisions --- including one that mandates new technology to prevent drunk driving.
4:00 a.m. Sept. 10, 2021 - By Tomi Kilgore
Apellis Pharmaceuticals stock plunges after disappointing result from GA treatment studies Shares of Apellis Pharmaceuticals Inc. plunged 31.6% toward a 10-month low to pace all premarket losers Friday, after one of the Phase 3 studies of the biopharmaceutical company's eye disease treatment failed to meet its primary endpoint. The company said late Thursday that the OAKS study for pegcetacoplan met the primary endpoint, as it significantly reduced geographic atrophy (GA) lesion growth, while the DERBY study missed its primary endpoint of GA lesion growth reduction. The company said it plans to submit a New Drug Application (NDA) for pegcetacoplan for GA to the U.S. Food and Drug Administration in the first half of 2022. Wedbush downgraded Apellis to neutral from outperform, saying the previous upgraded was predicated on both studies holding a "high probability of success," but the readout ended up in the "mixed bag" scenario. J.P. Morgan slashed its stock price target to $57 from $101, but kept its overweight rating, saying "patience required" but pegcetacoplan "likely gets across the goal line" eventually. Apellis' stock has shed 2.8% year to date through Thursday, while the iShares Biotechnology ETF has advanced 14.8% and the S&P 500 has gained 19.6%.
2:28 a.m. Sept. 10, 2021 - By Tomi Kilgore
Coronavirus tally: Daily average of new COVID-19 cases dips, but deaths rise to 6-month highThe global tally for the coronavirus-borne illness climbed to 223.23 million as of early Friday, while the death toll rose to 4,606,927, according to . The U.S. continues to lead the world with a total of 40.60 million cases and 654,598 deaths. The daily average of new cases over the past seven days was 147,816 as of Thursday, down from a recent peak of 166,105 on Sept. 1 and 5% less than what it was two weeks ago, according to . The daily average for deaths kept rising to 1,579, up 28% in two weeks and the most since March 9. The daily average for hospitalizations of 100,610 was down from a peak of 102,621 on Sept. 3 but up 1% from two weeks ago. The number of people that have been fully vaccinated grew to 177.43 million, or 53.4% of the total U.S. population, according to , while the number of people who have received at least one dose of a vaccine rose to 208.31 million, or 62.7% of the total population. In a speech from the White House late Thursday, President Joe Biden rolled out a " " to fight COVID-19, including new vaccine mandates, as he warned the country about a "tough stretch" in the fight against the delta variant.
12:59 a.m. Sept. 7, 2021 - MarketWatch.com
10 ways to improve your health and live longerThere are some astonishing new technologies on the horizon that will help you to 'grow young.' Why not be around to experience some of them?
12:09 p.m. Sept. 5, 2021 - MarketWatch.com
Facebook apologizes for 'primates' label on video of Black menFacebook has apologized for putting a “primates" label on a video of Black men, according to a report in the New York Times.
6:02 a.m. Sept. 4, 2021 - By Philip van Doorn
These robotics and automation stocks could climb up to 68% in the next yearWall Street loves these stocks owned by at least two of five ETFs focused on this long-term shift.
5:10 a.m. Sept. 4, 2021 - By Tonya Garcia
Burn in the USA: Why grill maker Weber has a big supply-chain advantage over its competitorsWeber coverage was initiated at a number of research groups, with many analysts noting the company's dominant market share and increased interest in outdoor grilling during the pandemic.
4:43 a.m. Sept. 4, 2021 - By Jeff Reeves
Forget short-term stock-market fads and just buy these 5 rocketing tech stocksJeff Reeves goes well beyond the FAAMNG stocks.
4:35 a.m. Sept. 4, 2021 - By Jaimy Lee
COVID-19 vaccine booster shots are more complicated than they appear. Here's why.One Wall Street analyst thinks that COVID-19 booster shots will only be available to people at higher risk of cases of COVID-19, and not all vaccinated Americans.
12:36 p.m. Sept. 3, 2021 - By John Scott Lewinski
Art Destined for Space Has an Earthly ImpactAn all-female artist collective is sending artworks into the stratosphere to advocate for Earth’s biodiversity
10:56 a.m. Sept. 3, 2021 - By Tomi Kilgore
Cassava Sciences CEO says 'enormous profit motive' behind N.Y. law firm's fraud allegationsCassava Sciences Inc.'s Chief Executive Remi Barbier repeated on Friday that recent allegations of fraud were "false and misleading" and were a result of investor interests to drive down the price of the biotechnology company's stock.
Browse topics:

Filter results by


Us (438)

Europe (90)

Asia Pacific (78)

Eu (66)

China (56)

Latin America (17)

Link to MarketWatch's Slice.